Stock Events

Palatin Technologies 

€1.49
104
-€0.09-5.8% Today

Statistics

Day High
1.49
Day Low
1.49
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
28.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.19
-0.84
-0.48
-0.13
Expected EPS
-0.5
Actual EPS
-0.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTN.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.72B
Amgen develops therapeutics in areas similar to Palatin, including reproductive health and cardiovascular diseases, making them direct competitors in the biopharmaceutical market.
Pfizer
PFE
Mkt Cap169.83B
Pfizer competes with Palatin in the development of novel drugs, including treatments in sexual health, where Palatin has a significant focus.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly offers products in men's health and other areas that overlap with Palatin's focus, particularly in treatments for conditions like erectile dysfunction.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie, with its broad range of pharmaceutical products, competes in the same therapeutic areas as Palatin, including women's health and hormonal therapies.
Merck &
MRK
Mkt Cap318.55B
Merck operates in various healthcare segments that compete with Palatin, including the development of drugs for sexual health and cardiovascular diseases.
Novartis
NVS
Mkt Cap232.42B
Novartis competes with Palatin in multiple areas, including cardiovascular and metabolic conditions, through its extensive research and development in these fields.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb's diverse range of pharmaceutical products in areas like cardiovascular diseases places it in competition with Palatin Technologies.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline has a presence in the sexual health market, making it a competitor to Palatin, especially in the development of treatments for related conditions.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca's work in cardiovascular and metabolic diseases competes with Palatin's research and development efforts in similar therapeutic areas.

About

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Show more...
CEO
Dr. Carl Spana Ph.D.
Employees
34
Country
US
ISIN
US6960775020
WKN
000A3DTUW

Listings